BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1258@pharmaconomics
DTSTAMP:20260707T003653Z
DTSTART;VALUE=DATE:20261001
DTEND;VALUE=DATE:20261002
SUMMARY:TLSA Phase 2 — intranasal foralumab
DESCRIPTION:Phase 2 trial results for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) are due Oct 1\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1723069/000121390026059919/ea029182901ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/1258
URL:https://pharmaconomics.com/e/1258
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TLSA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR